Vivifrail multicomponent exercise protocol
Vivifrail multicomponent exercise protocol has been studied in 1 paper since 2025: 1 trial in people. The newest paper, Mar 4, 2025: “Effects of the VIVIFRAIL Exercise Protocol on Circulatory and Intracellular Peripheral Mediators Bridging Mitochondrial Dynamics and Inflammation in Robust and Frail Older People”.
1 paper studies it4 findingsUpdated
See all 1 papers on vivifrail multicomponent exercise protocol
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Besides significant functional improvements across both groups”
None of its findings points the other way.
- 1 lab in 1 country
- Funder: Fondazione Cariplo
- Human trial1
Studies in people
1 study gave vivifrail multicomponent exercise protocol to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Improves physical function down: Decreases plasmatic ccf-mtDNA down: Decreases IL-6 | Trial12-week | 50 peoplemean 81.4 ± 5.6 years (frail)Older adults; both robust and frail groups | Aging cell, Mar 4, 2025 |
What did studies of vivifrail multicomponent exercise protocol find?
4Studies of vivifrail multicomponent exercise protocol measured 4 outcomes, among them apoptosis, IL-6 and plasmatic ccf-mtDNA.
Apoptosis
downin humans1
1 study
Apoptosis
downin humans1
Vivifrail multicomponent exercise protocol decreases apoptosis in humans (both groups).
“as well as reduced cellular damage/apoptosis (reduced plasmatic ccf-nDNA, downregulated BAX, and upregulated BCL-2/BAX ratio)”
Human trialboth groupsperipheral blood mononuclear cells12-week
Aging cell
IL-6
downin humans1
1 study
IL-6
downin humans1
Vivifrail multicomponent exercise protocol decreases IL-6 in humans (frail subjects only).
“plasmatic IL6 and IL6/IL10 ratio were reduced in frail subjects uniquely”
Human trialfrail subjects only12-week
Aging cell
Plasmatic ccf-mtDNA
downin humans1
1 study
Plasmatic ccf-mtDNA
downin humans1
Vivifrail multicomponent exercise protocol decreases plasmatic ccf-mtDNA in humans (robust subjects).
“Plasmatic ccf-mtDNA was significantly reduced in robust subjects”
Human trialrobust subjects12-week
Aging cell
Physical function
upin humans1
1 study
Physical function
upin humans1
Vivifrail multicomponent exercise protocol improves physical function in humans (both robust and frail groups).
“Besides significant functional improvements across both groups”
Human trialboth robust and frail groups12-week
Aging cell